SCHEMBL7629865

SCHEMBL7629865

Cc1cc(C(C)n2c(=O)[nH]c3ccc(C(=O)NCc4ccncc4)cc3c2=O)ccc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.43
MAPK3 P27361 1/20 0.43
B3GNT2 Q9NY97 1/20 0.43
PARP1 P09874 1/20 0.43
PIK3CA P42336 1/20 0.42
MAPT P10636 3/20 0.42
TP53 P04637 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
GAA P10253 3/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GLA P06280 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CDK1 P06493 1/20 0.40
CDK2 P24941 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432942 0.91 MAPK1 (0.46) MAPK1MAPK3B3GNT2PARP1PIK3CA
SCHEMBL6235396 0.89 MEN1 (0.52) B3GNT2MAPTTP53RXFP1GAA
SCHEMBL6232314 0.86 B3GNT2 (0.46) MAPK1MAPK3B3GNT2PARP1PIK3CA
SCHEMBL6233923 0.85 NAMPT (0.46) MAPK1MAPK3B3GNT2PARP1PIK3CA
SCHEMBL7104616 0.85 NAMPT (0.46) MAPK1MAPK3B3GNT2PARP1MAPT
SCHEMBL27605972 0.83 B3GNT2 (0.44) MAPK1MAPK3B3GNT2PARP1MAPT
SCHEMBL6236712 0.82 MEN1 (0.52) B3GNT2MAPTTP53GAAALDH1A1
SCHEMBL6727454 0.82 MEN1 (0.50) B3GNT2MAPTTP53GAAALDH1A1
SCHEMBL6232533 0.81 MEN1 (0.53) B3GNT2MAPTTP53RXFP1GAA
SCHEMBL6238482 0.81 MEN1 (0.51) B3GNT2MAPTTP53RXFP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MAPK1 1676/4885MAPK3 1031/4885B3GNT2 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.